Avanzanite
London, England, United Kingdom · Biotechnology, Pharmaceutical · 28 employees
Avanzanite is redefining launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the Netherlands, the company partners with biotech innovators to unlock the full commercial value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe’s complex landscape like master chess players – ensuring no patient is left behind while d
Funding history
- Series series a — $32.0M — Nov 2025
Recent signals
- Mar 24, 2026: Avanzanite Bioscience Appoints Constance Sabbagh as General Manager
- Nov 18, 2025: Raised $32.0M in Series series a
- Oct 14, 2025: Avanzanite Appoints Giovanni Galliano as General Manager for Italy
- Jun 09, 2025: Avanzanite Forms Exclusive Partnership with Agios to Enhance Distribution of PYRUKYND® in Europe.
- Feb 03, 2025: Avanzanite Bioscience Appoints Abdel Omari as Chief Financial Officer
- Jan 13, 2025: Avanzanite Bioscience B.V. Appoints Jason Cameron as Chief Technology Officer
See plans & pricing → Track Avanzanite’s funding, hiring, and signals — with verified contacts — on Fundz.